AC50 (functional)
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active
|
ChEMBL.
|
No reference
|
AC50 (functional)
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active
|
ChEMBL.
|
No reference
|
AC50 (functional)
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active
|
ChEMBL.
|
No reference
|
AC50 (functional)
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active
|
ChEMBL.
|
No reference
|
AC50 (functional)
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active
|
ChEMBL.
|
No reference
|
GI (functional)
|
|
Herbicidal activity against Arabidopsis thaliana assessed as growth inhibition at 10 ppm by 96-well plate test
|
ChEMBL.
|
21970768
|
GI50 (functional)
|
-4
|
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
GI50 (functional)
|
-4
|
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
GI50 (functional)
|
-4
|
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
GI50 (functional)
|
-4
|
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
GI50 (functional)
|
-4
|
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
GI50 (functional)
|
-4
|
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
GI50 (functional)
|
-4
|
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
GI50 (functional)
|
-4
|
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
GI50 (functional)
|
-4
|
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon))
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Chemokine CXCR1 (IL-8A)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA))
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 2 uM
|
Tested for the inhibition against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 2 uM
|
Tested for the inhibition against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
= 12 uM
|
Inhibition of Thlaspi arvense CPR-fused CYP71B1 expressed in Escherichia coli DH5alpha assessed as conversion of benzo(a)pyrene to 3-hydroxybenzo(a)pyrene
|
ChEMBL.
|
9514851
|
IC50 (binding)
|
= 100 uM
|
Inhibition of glutamine synthetase in Nicotiana tabacum (tobacco) cells
|
ChEMBL.
|
17474756
|
IC50 (binding)
|
= 100 uM
|
Inhibition of Spinacia oleracea (spinach) glutamine synthetase activity
|
ChEMBL.
|
17474756
|
Inhibition (ADMET)
|
= 99.87449448 %
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
ChEMBL.
|
23571415
|
Inhibition (ADMET)
|
= 130.3183724 %
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
ChEMBL.
|
23571415
|
Kd (binding)
|
= 0.16 uM
|
Tested for the dissociation constant against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase
|
ChEMBL.
|
No reference
|
Kd (binding)
|
= 0.16 uM
|
Tested for the dissociation constant against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA))
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Chemokine CXCR1 (IL-8A)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon))
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
= 0.16 uM
|
Tested for the inhibition against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase versus phosphoenolpyruvate
|
ChEMBL.
|
No reference
|
Ki (binding)
|
= 0.16 uM
|
Tested for the inhibition against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase versus phosphoenolpyruvate
|
ChEMBL.
|
No reference
|
Ki (binding)
|
= 260 uM
|
Competitive inhibition of Neisseria meningitidis serotype B strain MC58 ATCC BAA355 KDO8P synthase expressed in Escherichia coli BL21 (DE3) cells using PEP as substrate after 10 to 15 mins by Michaelis-Menten equation
|
ChEMBL.
|
22204912
|
Koff (binding)
|
= 0.12 s-1
|
Tested for the dissociation rate against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase
|
ChEMBL.
|
No reference
|
Kon (binding)
|
= 0.78 uM-1 s-1
|
Tested for the rate of association against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase
|
ChEMBL.
|
No reference
|
Ks (binding)
|
= 60 uM
|
Binding affinity to Thlaspi arvense CPR-fused CYP71B1 expressed in Escherichia coli DH5alpha
|
ChEMBL.
|
9514851
|
k_off (binding)
|
= 0.12 s-1
|
Tested for the dissociation rate against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase
|
ChEMBL.
|
No reference
|
k_on (binding)
|
= 0.7799999999999999 uM-1 s-1
|
Tested for the rate of association against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase
|
ChEMBL.
|
No reference
|
k_on (binding)
|
= 0.78 uM-1 s-1
|
Tested for the rate of association against E. coli 5-enolpyruvyl-shikimate-3-phosphate synthase
|
ChEMBL.
|
No reference
|